RxDoctor Payments Data

Andrew Poklepovic, MD

Internal Medicine · Richmond, VANPI 1356550800

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (58.0%), consulting fees and food and beverage — rather than concentrated in one kind of arrangement. E.r. Squibb & Sons, L.L.C. accounts for 75.0% of it on its own, with 8 other manufacturers making up the rest. Reporting peaked in 2020 at $23,030 and has fallen 98.9% since, to $247 in 2025. Among internal medicine clinicians in VA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$58,131in general payments, 2019–2025

Across 61 payments — averaging $952.97 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • E.r. Squibb & Sons, L.L.C.$44K
  • Novartis$8K
  • Bristol Myers Squibb$6K
  • Springworks Therapeutics, Inc.$228
  • Eisai Inc.$105
  • Merck$97
  • plus $56 from 3 others
$4,578,965in research payments, 2019–2025

Across 161 payments — averaging $28,441 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • GSK$2.5M
  • Merck$1.1M
  • E.r. Squibb & Sons, L.L.C.$339K
  • Incyte Corporation$223K
  • Iovance Biotherapeutics, Inc.$130K
  • Ascendis Pharma Endocrinology Inc$112K
  • plus $223K from 4 others

What the payments were for

  • Consulting fees$22,60839%
  • Speaking & faculty fees$33,71558%
  • Travel & lodging$5681%
  • Food & beverage$1,2262%
  • Education$150%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$58,131 in reported general payments places this provider in the 95th percentile of 2,724 internal medicine providers in Virginia.

See all internal medicine providers in Virginia

Medicare billing

Part B allowed, 2024
$61,101
Medicare patients
194
Services billed
640

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
BraftoviEncorafenib15$218,050
MektoviBinimetinib15$213,936
Ondansetron Hcl15$358
Oxycodone Hcl18$337
Prochlorperazine Maleate12$164
Prednisone21$125
Tramadol Hcl12$117
Levothyroxine Sodium12$24

Paid to pharmacies, not to this prescriber.

Other internal medicine in Richmond

See the full list for Virginia

Where these figures come from

Is this you, or does something look wrong? →